價(jià)格 | 詢價(jià) | ||
包裝 | 1支 | 1支 | 1支 |
最小起訂量 | 1支 |
發(fā)貨地 | 湖北 |
更新日期 | 2025-02-12 |
英文名稱:Research Grade Romlusevimab (DVV00312) | CAS:2509447-08-7 |
純度規(guī)格: PAGE:>95% | 產(chǎn)品類別: 藥物對(duì)照抗體 |
抗體名: Research Grade Romlusevimab (DVV00312) | 靶點(diǎn): Spike glycoprotein |
宿主: Homo sapiens | 適應(yīng)物種: SARS-CoV-2 (2019-nCoV) |
克隆性: Monoclonal | 藥物對(duì)照抗體: Research Grade Romlusevimab (DVV00312) |
Catalog No.
DVV00312
Host species
Homo sapiens
Species reactivity
SARS-CoV-2 (2019-nCoV)
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1.99 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, lambda2
Applications
Research Grade Biosimilar
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2, Receptor-Binding Domain, RBD
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P0DTC2-2
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
BRII 198, BRII-198, BRII198 CAS: 2509447-08-7, SARS-like Coronaviruses
Note
For research use only. Not suitable for clinical or therapeutic use.
成立日期 | 2021-04-08 (4年) | 注冊(cè)資本 | 700萬 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1000萬-5000萬 |
主營行業(yè) | 生物化工,技術(shù)服務(wù) | 經(jīng)營模式 | 試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
碧云天生物技術(shù)有限公司
|
2025-01-30 | ||
詢價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2024-12-30 | |
詢價(jià) |
VIP4年
|
武漢艾美捷科技有限公司
|
2025-02-05 |